close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Marius Pharmaceuticals LLC

News headline image
Marius Pharmaceuticals to Initiate Study Evaluating KYZATREX® (testosterone undecanoate) CIII Capsules in Men Ages 65–80
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals CEO Shalin Shah Invited to Speak at Landmark FDA Expert Panel on Testosterone Replacement Therapy for Men
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Expands Global Footprint with Health Canada Approval of KYZATREX® (testosterone undecanoate) CIII Capsules
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Leads Effort to Redefine Women’s Health Through Testosterone Research
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Receives Sixth U.S. Patent Allowance for KYZATREX® (testosterone undecanoate) CIII Capsules Extending Coverage to 2040
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Welcomes John "Shrek" Mcphee as Kyzatrex® (testosterone undecanoate) CIII Capsules Patient Ambassador
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Partners with Major Academic Medical Center on Education and Research Efforts for Oral Testosterone
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Helps Drive FDA’s Landmark Testosterone Label Update, Removing Black Box Warning
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Unveils New Corporate Website and Announces Longevity & Endocrinology Advisory Boards
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Announces KYZATREX® (testosterone undecanoate) CIII Capsules Availability Through Thrive, Expanding Men's Health Solutions
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Partners with US Specialists Management, LLC (“USSM”) Through Affiliated Urologic In-office Dispensaries
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
KYZATREX® (testosterone undecanoate) CIII Capsules EXPANDS DISTRIBUTION THROUGH NEW COLLABORATION WITH GAMEDAY MEN’S HEALTH
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
The Testosterone Project Launches on National Testosterone Awareness Day, November 17
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Partners with UK-Based Numan to Combat Testosterone Deficiency with KYZATREX® (Testosterone Undecanoate) CIII Capsules
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
From Marius Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
From Marius Pharmaceuticals LLC
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today